作者: Mehdi Farhoudi , Mahdi Najafi-Nesheli , Mazyar Hashemilar , Ata Mahmoodpoor , Ehsan Sharifipour
关键词:
摘要: Considering the role of inflammation in acute cerebrovascular accidents, anti-inflammatory treatment has been considered as an option diseases. Regarding properties Setarud (IMOD™) immune regulation, aim present study was to evaluate this medication treating patients with ischemic stroke. In randomized clinical trial, 99 their first ever stroke were divided into two groups IMOD™ (n = 49) and control (n = 50). The group underwent routine intervention plus daily intermittent infusion (250mg on day then 375mg DW5% serum during a 30-minute period for 7 days). levels inflammatory markers evaluated (baseline) 4th 7th days. Data analyzed results compared. 58 males (58.6%) 41 females (41.4%) mean age 67.00 ± 8.82 years, who had attack, enrolled trial. Treatment showed decreasing trend IL-6 compared (p = 0.04). addition, resulted increasing hsCRP after days (p = 0.02). There insignificant decrease TNF-α IL-1 group. prominent cerebral damage, it appears that improves profile. Therefore, (Setarud) might be therapeutic However, future studies are necessary its long-term efficacy.